Posted by Michael Wonder on 05 Dec 2024
Results of health technology assessments of orphan drugs in Germany—lack of added benefit, evidence gaps, and persisting unmet medical needs
3 December 2024 - The number of orphan drug approvals has increased sharply in Europe. In Germany, all orphan drugs are initially subject to a limited assessment after market access.
Their added benefit over the standard of care is accepted as established upon EU approval; a regular health technology assessment is performed only in certain cases.
Read International Journal of Technology Assessment in Health Care article
